Wow, sprb now down 76% at 1.27 - said it would terminate its CAHmelia-203 study, which was evaluating tildacerfont to treat adult classic congenital adrenal hyperplasia And here is the pipeline - looks like a one drug co: https://sprucebio.com/pipeline/tildacerfont/
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.